Perampanel

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Perampanel

Examples of brand names: Fycompa [EU/DE]

ATC code: N03AX22

Main use (for orientation): Epilepsy

Documented research summary

Open-label CBD cohort: concentration increase only in the adult analysis; no controlled quantification. A status epilepticus case involving five antiseizure medicines plus CBD does not permit an isolated perampanel drug–drug interaction conclusion.

Uncertainties and limitations

Multiple testing, small subgroup and dose adjustments limit the open-label analysis.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – clinical signals

Finding ID: B0056

Type of result: Positive finding / indication

Observation: Serum concentration ↑; p=<0.0001.

Mechanism: Mechanism uncertain

Study type: Observational study

Context studied: 17 overall (4 adults, 13 children); positive signal only in the adult subgroup, n=4.

Clinical interpretation: Clinical significance unclear

Limitations and uncertainties: Association; CL20 context/limitations.

Original sources for this finding: Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program [CL20]

References and access status

[CA_L_D0054] FYCOMPA (PERAMPANEL) TABLET FYCOMPA (PERAMPANEL) SUSPENSION [EISAI INC.]

Original source / bibliographic reference

Authors: Eisai Inc.

Year: 2022

Source type: Current published human-use SPL / product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CL20] Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program

Original source / bibliographic reference

Authors: Gaston TE; Bebin EM; Cutter GR; Grayson L; Szaflarski JP

Year: 2023

Source type: Open-label longitudinal observational study

DOI: 10.1002/epi4.12815

PMID: 37593907

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility